2 minute read
Fosamax (alendronate), a widely used osteoporosis drug, remains the subject of multidistrict litigation (MDL) over allegations that it can cause serious bone injuries, including atypical femur fractures and osteonecrosis of the jaw (ONJ). Plaintiffs claim Merck failed to warn users adequately about these risks .
Latest Updates
Significant recent developments have revived thousands of Fosamax femur fracture lawsuits that were previously dismissed. In September 2024, a federal appeals court ruled that these cases could proceed . The U.S. Supreme Court declined to review this decision in June 2025, allowing the litigation to move forward in New Jersey federal court .
Plaintiffs continue to assert that Fosamax’s impact on bone remodeling increases fracture risks and that Merck did not sufficiently update warning labels despite FDA concerns dating back to the early 2000s.
Signature Injury
The signature injuries associated with the Fosamax MDL are atypical femur fractures and osteonecrosis of the jaw, both believed to be linked to long-term use of Fosamax .
Contact Us
If you or a loved one experienced femur fractures or jaw problems after taking Fosamax, legal options may still be available. Prompt legal advice is important as deadlines approach. Contact the Michael Brady Lynch Firm at 888-585-5970 today to discuss your legal options.
Date: August 12, 2025
Attorney and Editor-in-Chief: Brandon Salter
Editor: Madison Hurley
Citations:
https://www.njcourts.gov/multicounty-litigation/fosamax/case-information
https://www.reuters.com/legal/litigation/court-revives-more-than-500-lawsuits-over-fosamax-femur-fracture-risk-2024-09-20/
https://www.law.com/njlawjournal/2025/06/17/hundreds-of-revived-fosamax-lawsuits-allowed-to-move-forward-as-us-high-court-denies-mercks-bid-for-appeal/?slreturn=20250731125301